Veerhealth Care Past Earnings Performance
Past criteria checks 2/6
Veerhealth Care has been growing earnings at an average annual rate of 46.2%, while the Pharmaceuticals industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 11.2% per year. Veerhealth Care's return on equity is 1.9%, and it has net margins of 2.8%.
Key information
46.2%
Earnings growth rate
32.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 11.2% |
| Return on equity | 1.9% |
| Net Margin | 2.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Veerhealth Care makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 146 | 4 | 13 | 0 |
| 31 Dec 23 | 148 | 19 | 15 | 0 |
| 30 Sep 23 | 149 | 21 | 15 | 0 |
| 30 Jun 23 | 153 | 18 | 10 | 0 |
| 31 Mar 23 | 142 | 16 | 13 | 0 |
| 31 Dec 22 | 127 | 2 | 13 | 0 |
| 30 Sep 22 | 125 | 1 | 13 | 0 |
| 30 Jun 22 | 115 | -1 | 9 | 0 |
| 31 Mar 22 | 108 | -1 | 12 | 0 |
| 31 Dec 21 | 107 | 1 | 9 | 0 |
| 30 Sep 21 | 118 | 0 | 8 | 0 |
| 30 Jun 21 | 127 | 4 | 8 | 0 |
| 31 Mar 21 | 114 | 4 | 8 | 0 |
| 31 Dec 20 | 122 | -1 | 9 | 0 |
| 30 Sep 20 | 105 | 0 | 9 | 0 |
| 30 Jun 20 | 113 | 2 | 8 | 0 |
| 31 Mar 20 | 118 | 3 | 9 | 0 |
| 31 Dec 19 | 105 | 4 | 12 | 0 |
| 30 Sep 19 | 100 | 6 | 11 | 0 |
| 30 Jun 19 | 70 | 2 | 5 | 0 |
| 31 Mar 19 | 60 | 2 | 10 | 0 |
| 31 Dec 18 | 53 | 0 | 8 | 0 |
| 30 Sep 18 | 52 | -1 | 9 | 0 |
| 30 Jun 18 | 55 | 2 | 6 | 0 |
| 31 Mar 18 | 52 | 1 | 9 | 0 |
| 31 Dec 17 | 39 | 7 | 6 | 0 |
| 30 Sep 17 | 33 | 5 | 6 | 0 |
| 30 Jun 17 | 23 | 0 | 6 | 0 |
| 31 Mar 17 | 21 | 0 | 6 | 0 |
| 31 Dec 16 | 16 | 3 | 6 | 0 |
| 30 Sep 16 | 18 | 4 | 7 | 0 |
| 30 Jun 16 | 23 | 2 | 9 | 0 |
| 31 Mar 16 | 22 | 0 | 10 | 0 |
| 31 Dec 15 | 24 | -1 | 11 | 0 |
| 30 Sep 15 | 17 | -2 | 10 | 0 |
| 30 Jun 15 | 15 | -1 | 6 | 0 |
| 31 Mar 15 | 13 | 1 | 5 | 0 |
| 31 Dec 14 | 34 | -1 | 5 | 0 |
| 30 Sep 14 | 31 | -1 | 4 | 0 |
| 30 Jun 14 | 35 | 0 | 4 | 0 |
| 31 Mar 14 | 30 | 0 | 3 | 0 |
| 31 Dec 13 | 31 | 0 | 2 | 0 |
| 30 Sep 13 | 36 | -1 | 2 | 0 |
| 30 Jun 13 | 32 | 0 | 2 | 0 |
Quality Earnings: 511523 has high quality earnings.
Growing Profit Margin: 511523's current net profit margins (2.8%) are lower than last year (11.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 511523's earnings have grown significantly by 46.2% per year over the past 5 years.
Accelerating Growth: 511523's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 511523 had negative earnings growth (-74.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (18.2%).
Return on Equity
High ROE: 511523's Return on Equity (1.9%) is considered low.